BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT04536961
- Locations
- 🇬🇧
Quotient Sciences Miami, Nottingham, United Kingdom
Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT04515628
- Locations
- 🇺🇸
ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Phase 4
Completed
- Conditions
- Kidney Neoplasms
- Interventions
- Biological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 101
- Registration Number
- NCT04513522
- Locations
- 🇮🇳
Local Institution - 0002, Karnataka, India
🇮🇳Local Institution - 0007, New Delhi, Delhi, India
🇮🇳Local Institution - 0011, Trivandrum, Kerala, India
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
Active, not recruiting
- Conditions
- Lung Cancer
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 698
- Registration Number
- NCT04500535
- Locations
- 🇫🇷
Local Institution - 0001, Paris Cedex 5, France
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
Phase 2
Withdrawn
- Conditions
- Melanoma
- Interventions
- Biological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04495010
- Locations
- 🇬🇧
Local Institution, Sutton, United Kingdom
A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
Phase 1
Completed
- Conditions
- Lupus Erythematosus, Cutaneous
- Interventions
- Other: BMS-986256 Placebo
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT04493541
- Locations
- 🇩🇪
Local Institution - 0001, Berlin, Germany
Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04493567
- Locations
- 🇺🇸
ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
Phase 2
Terminated
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- Other: PlaceboBiological: Abatacept
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT04472494
- Locations
- 🇺🇸
Atlantic Health System, Morristown, New Jersey, United States
🇵🇷CardioPulmonary Research, Guaynabo, Puerto Rico
🇵🇷Ponce Medical School Foundation, Ponce, Puerto Rico
Participant Reported Outcomes and Treatment Experiences in Kidney Cancer
Completed
- Conditions
- Kidney Cancer
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT04472663
- Locations
- 🇺🇸
Local Institution, Morristown, New Jersey, United States
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT04470778
- Locations
- 🇺🇸
ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath